US 12,427,180 B2
Treatment of respiratory tract diseases and infections with ascorbic acid compositions
Dan Copeland, Chapel Hill, NC (US); Carolyn Durham, Chapel Hill, NC (US); and Thomas E. Richardson, Chapel Hill, NC (US)
Assigned to RENOVION, INC., Chapel Hill, NC (US)
Filed by RENOVION, INC., Chapel Hill, NC (US)
Filed on Jan. 27, 2023, as Appl. No. 18/160,513.
Application 18/160,513 is a continuation of application No. 16/461,671, granted, now 11,602,555, previously published as PCT/US2017/062412, filed on Nov. 17, 2017.
Claims priority of provisional application 62/423,702, filed on Nov. 17, 2016.
Claims priority of provisional application 62/423,721, filed on Nov. 17, 2016.
Prior Publication US 2023/0165929 A1, Jun. 1, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/06 (2006.01); A01N 37/30 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 47/22 (2006.01); A61P 11/00 (2006.01); A61P 31/04 (2006.01)
CPC A61K 38/063 (2013.01) [A01N 37/30 (2013.01); A61K 9/0073 (2013.01); A61K 9/19 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/22 (2013.01); A61P 11/00 (2018.01); A61P 31/04 (2018.01)] 30 Claims
 
1. A method of treating a subject suffering from or at risk for a chronic clinical isolate bacterial infection comprising administering to the subject a composition comprising (a) glutathione or a pharmaceutically-acceptable salt thereof, and (b) ascorbic acid or a pharmaceutically acceptable salt thereof, wherein the composition (i) inhibits or reduces growth of a clinical isolate bacteria or (ii) inhibits or reduces formation of a clinical isolate bacteria biofilm;
wherein the clinical isolate bacteria is selected from the group consisting of Burkholderia cepacia, methicillin resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, Moraxella catarrhalis, Stenotrophomonas maltophilia, and Acinetobacter baumannii.